Michael B Schachter MD, CNS

Schachter Center for Complementary Medicine 2 Executive Boulevard Suite 202 Suffern, New York 10901 Phone: 845-368-4700; FAX: 845-368-4727 Website: <u>www.schachtercenter.com</u> E-Mail: www.office@mbschachter.com

Supporting Body Defenses against Breast Cancer with Avemar & AHCC

8th Annual Complementary Medicine Conference: "A Holistic Approach to Breast Health": SUNY New Paltz, NY April 19, 2009

Disclosures

- Xymogen
 - Board of Advisors
 - Own some shares in company (< 1%)
- American Bioscience Inc.
 - Small honorariums for occasional lectures
- Maitake Products, Inc.
 - Will support trip to Japan with honorarium this summer to lecture about CAIM and Cancer
- Natural Source (Producers of Beljanski products) - Rare support for lecture

Tools

- Available as handouts at the American BioScience booth and at our website: <u>www.schachtercenter.com</u>
 - Brief summary handout of Dr. Schachter's views on Cancer and CAIM
 - Cancer Reading List
 - Cancer Website List
 - Avoid and To Do List



Conventional Cancer Therapies for Breast Cancer

- Surgery
- Radiation Therapy
- Chemotherapy
- Hormonal or anti-hormonal therapies (like Tamoxifen, Arimidex or Lupron)
- Monoclonal antibodies inhibit one of the steps of the cancer process (like Herceptin or Avastin); Newest drugs (there are many)

Focus of Conventional Cancer Treatment

- Destroy cancer cells with once of conventional treatments
- Not much emphasis on lifestyle, good nutrition
- Patients often told to avoid all nutritional supplements, as they might interfere with conventional treatment
- Measure progress by tumor shrinkage—Not a good measure of progress

Goals of Integrative Treatment for Breast Cancer

- Prevent breast cancer
- Help prevent recurrences
- Focus on survival and quality of life
- Support conventional treatment with various methods to improve results and reduce adverse effects of conventional treatment
- Methods emphasize, non-invasive, selective treatments that focus on lifestyle, nutrition, nutritional supplements, exercise, stress management, energy balancing
- Help patients make decisions about conventional treatment

Integrative Evaluation of the Cancer Patient

- Focus on patient as a person
- Assess strengths and weaknesses
- Evaluate support system
- Full clinical history & physical examination for many practitioners (MD, DO, PA-C, NP, etc)
- Assess current lifestyle factors
- Assess patient's ability to make changes
- Nutritional and Laboratory testing

Integrative Laboratory Testing for the Cancer Patient

- Complete routine labs
- Check certain nutrients levels (especially vitamins A and D, selenium, others)
- Check heavy metal toxicity (levels of lead, cadmium and mercury)
- Check appropriate cancer markers (e.g. CEA, CA19-9, CA27-29)
- Check for immune function

Integrative Cancer Therapies May Include-1

- Dietary suggestions-cornerstone-organic food (reduced toxins-increased nutrientsphytonutrients as information)-Quillin-Raw, Live Food Organic diet
- Avoid poor quality food and toxic exposures (See my website: Avoid & To Do List)
- Lifestyle changes-Exercise-Stress Management-Sunlight Exposure-Sleep
- Oral nutritional supplements

Integrative Cancer Therapies May Include-2

- Detoxification-Bowel, Liver, Skin, Saunas
- Injectable treatments-C drips, B17
- Energy treatments-Homeopathy, Acupuncture
- Attempt to deal with attitude, stress and spiritual elements
- Help with decisions relating to conventional treatment

What Questions a Patient or Support Person Should Ask?

- Likelihood survival time will be increased (Clinical response is NOT so important)
- Likelihood quality of life will be improved
- Risks associated with the treatment:
 - Morbidity
 - -Mortality
 - -Secondary cancers

Example: Standard of Care for Stage I & II Breast Cancer

- Lumpectomy
- Radiation therapy
- Chemotherapy in most cases
- Anti-hormonal therapy if cancer is estrogen receptor positive
- Possible monoclonal therapy drug (like Herceptin) if HER2/Nu positive
- Can look at all of these, but we'll focus on radiation

Radiation and the Treatment of Breast Cancer A Cancer Decisions[®] Report (Ralph Moss)

- Reduces risk of a recurrence in the same breast
- Does NOT reduce regional recurrence or distant metastases
- No impact on overall survival with increased deaths from causes other than breast cancer.
- Harmful effects (e.g. heart damage, lymphedema) may occur later
- See: <u>www.cancerdecisions.com</u> for report

Should Radiation be Automatic for Breast Cancer?

- So, should women automatically accept radiation for breast cancer after lumpectomy
- Many breast cancer patients refuse radiation and do intensive integrative program after lumpectomy
- Change the milieu in which cancer developed in the first place

Integrative Therapeutic Approach for Cancer Patients

- Go to basics of nature and nurture
- Power of food to harm or heal- overlooked by medical practitioners and consumers alike.
- Role of nutrition in preventing cancer recognized for decades (Thousands of research articles; Recognized: NCI, ACS, AICR)
- But, role in healing cancer—ignored by oncologists-cancer organizations

 Susan Silberstein PhD; www.beatcancer.org

Move Toward Nature

- "Whatsoever is the father of disease, poor diet is the mother." (Chinese Proverb)
- "All mankind needs for health and healing is provided in nature." (Paracelsus, Father of pharmacology)
- "Natural forces within us are the true healers. Let thy food be thy medicine and thy medicine be thy food" Hippocrates: The Father of Medicine

Estimates of CA deaths avoidable by dietary change (from NCI)

- Prostate 75%
- Colon/rectum 75%
- Breast 70%
- Endometrium, Gall Bladder 50%
- Stomach 35%

Effects of Dietary Change on Diagnosed Cancer

- Avoidance of malnutrition
- Minimization of treatment side effects
- Optimization of cytotoxic effects
- Protection of healthy tissue
- Healthy cell proliferation
- Immune enhancement
- Hormonal changes

Epigenetics and Cancer

- Epigenetics refers to how our environment affects gene manifestations
- With cancer pro-cancer genes are switched on and anti-cancer genes are switched off
- The typical American diet upregulates cancer genes and downregulates anticancer genes
- The organic, raw, vegan diet upregulates anticancer genes and downregulates procancer genes

Supplements for Cancer Patients: Yes or No?

- Selective agents that inhibit or kill cancer cells, but do not harm normal cells
- Treatments that strengthen rather than weaken the body and the body's defenses against cancer
- What about notion that cancer patients should avoid supplements when undergoing radiation or chemotherapy?

Chemotherapy & Antioxidant Supplementation-Keith Block MD

- Reviewed 845 peer-reviewed articles
- Identified 19 clinical trials-met strict inclusion criteria.
- Most study participants-advanced or recurrent disease given various supplements.
- Conclusion: "None of the trials reported evidence of significant decreases in efficacy from antioxidant supplementation during chemotherapy."

(2) Chemotherapy & Antioxidant Supplementation-Keith Block MD

- Many studies showed that antioxidant supplementation was associated with "increased survival times, increased tumor responses, or both, as well as fewer toxicities than controls"
- Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic efficacy: A systematic review of the evidence from randomized controlled trials. *Cancer Treat Rev. 2007 Mar 14*

Charles Simone MD (Radiation Oncologist and Chemotherapist)

 "Since the 1970s, 280 peer-reviewed in vitro and in vivo studies, including 50 human studies involving 8,521 patients, 5,081 of whom were given nutrients, have consistently shown that non-prescription antioxidants and other nutrients do not interfere with therapeutic modalities for cancer. Furthermore, they enhance the killing of therapeutic modalities for cancer, decrease their side effects, and protect normal tissue. In 15 human studies, 3,738 patients who took nonprescription antioxidants and other nutrients actually had increased survival."

Charles Simone's References

- Charles B. Simone II, MD; Nicole L. Simone, MD; Victoria Simone, RN; Charles B. Simone, MD. ANTIOXIDANTS AND OTHER NUTRIENTS DO NOT INTERFERE WITH CHEMOTHERAPY OR RADIATION THERAPY AND CAN INCREASE KILL AND INCREASE SURVIVAL, PART 1 and 2. Altern Ther Health Med. Jan-Feb, and Mar-Apr, 2007;13(1):22-28; 13(2): 40-7.)
- Simone CB, Simone NL, Simone CB II. Oncology Care Augmented with Nutritional and Lifestyle Modification. J Ortho Mol Med. 1997; 12(4): 197-206.
- Simone CB. Cancer and Nutrition, A Ten Point Plan for Prevention and Cancer Life Extension. Princeton Institute. 2006.

Eight Clusters of Procancer Events John Boik

- 1-Gene mutations and genetic instability
- 2-Gene expression (Switching on and off)
- 3-Abnormal signal transduction
- 4-Abnormal cell to cell communication
- 5-New blood vessel formation-angiogenesis
- 6-Invasion into tissues
- 7-Metastasis to other organs
- 8-Immune suppression and other forms of immune evasion

Natural Compounds in Cancer Therapy-2001

1-Genetic Mutations

- Proto-oncogenes become oncogenes
 - Examples are Ras gene mutations
 - Ras gene mutation present in 20 to 30% of human cancers
 - Accelerators or promoters of cancers
- Tumor suppressor gene mutations
 - Example is P53
 - Present in about 50% of human cancers
 - Brakes or inhibitors of cancers

In cancer, oncogenes are over-active and tumor suppressor genes are under active

Causes of Mutations

- Toxic Exposures
 - Toxic elements (e.g. lead, mercury, fluoride)
 - Organic toxins (e.g. pesticides, chemicals in
 - plastics, xenoestrogens)
 - Radiation exposure
- Insufficient protective factors
 - Lack of antioxidants (e.g. vitamins A, C, E, and minerals such as selenium)
 - Sunlight in optimal amounts

2-Genetic Expression or Turning the Genes On or Off

- We have 30,000 genes in each cell
- Only about 3,000 active at one time
- There are switches that turn genes on or off either temporarily or permanently
- In cancer, oncogenes are turned on and tumor suppressor genes are turned off
- To treat cancer, do the opposite
- Burzynski's antineoplastons act as switches to fight cancer
- Various phytonutrients found in raw fruits and vegetables do the same thing

3-Abnormal Signal Transduction

- Cancer cells have abnormally high growth factor receptors (e.g. insulin growth factor)
- Various growth factors stimulate receptors
- Cancer cells produce the growth factors themselves
- Growth signal is transduced by various proteins (e.g. protein tyrosine kinase) to the nucleus to induce rapid growth (like passing a baton)
- Many new monoclonal drugs like Herceptin interfere with one of these transduction steps
- Various natural substances can inhibit this process in various ways (e.g. EPA inhibits protein tyrosine kinase) <u>Signal transduction</u> is any process by which a biological cell converts one kind of signal or stimulus into another

4-Abnormal Cell to Cell Communication

- Normal cells interact with and control each other via cell adhesion molecules and gap junction communication
- Cancer cells break off communication and behave like renegades
- Various natural substances (e.g. melatonin, Resveratrol) tend to re-establish and normalize communication

5-New Blood Vessel Formation: Angiogenesis

- Cancer requires new blood vessels in order to grow
- Cancer cells produce molecules to stimulate angiogenesis
- Natural substance Angiostatin (modified into a drug is approved for breast cancer treatment)
- Natural substances (e.g. certain proteins from shark cartilage) inhibit angiogenesis
- Copper depletion inhibits angiogenesis
- Read the book: Dr. Folkman's War- by Robert Cooke for a better understanding

6-Invasion of Tissues

- Cancer cells secrete enzymes to break down the surrounding tissue
- Weakness in the tissues allows this
- Natural substances (e.g. vitamin A, vitamin C and Curcumin) may strengthen the matrix
- Natural substances (e.g. Boswellic acids, Proanthocyanidins from grape seed) inhibit the enzymes that break down the tissue

7-Metastasis

- Cancer cells travel to distance organs and grow
- 5 step process
 - Cell detachment and entrance into bloodstream
 - Migration through the circulation
 - Arrest in a new location
 - Exit from bloodstream into tissues
 - Cell proliferation and new blood vessel formation

7-Metastasis-(cont)

- Immune system may help prevent metastasis
- Platelet aggregation and fibrin production enhance metastasis-allow cancer cells to stick in location
- Natural substances (e.g. proteolytic enzymes, EPA, vitamin E) counteract platelet aggregation and fibrin production

8-Immune Suppression and Other **Forms of Immune Evasion**

- Immune system plays some role in controlling cancer
- Non-specific mechanisms (e.g. natural killer cells)
- Specific mechanisms (e.g. cytotoxic killer T cells)
- Various natural substances enhance immune function

Killing Cancer Cells: Apoptosis vs. Necrosis

Apoptosis

- Programmed cell death Violent cell death
- Individual cells
- Cell membranes don't Cell membranes rupture rupture
- No inflammation ٠
- Orderly and preferred
- Large groups of cells die

Necrosis

- Inflammation present
- Disorderly and less desirable

Using Natural Non-Toxic Substances to Prevent and Treat Cancer

- Mild relatives to chemotherapy drugs—30 times less potent in vitro
- About 21 times less toxic than most chemotherapy drugs
- Each substance acts at several steps of cancer process
- · Synergistic effects-must be used in combination



U.S. Patent 6,355,474

Aarch 12, 2002

Avemar: A truly remarkable natural product

Development initiated many years ago by Dr. Albert Szent-Gyorgyi, a recipient of the Nobel Prize in Medicine.

Produced by a patented process that yields a uniform, consistent all-natural dietary supplement.

More than 100 reports have been written for presentation or publication describing research conducted in the United States, Hungary, Russia, Austria, Israel and Italy.

Validated by the publication of more than 18 peer-reviewed studies accessible by Medline.

History

- Albert Szent-Gyorgyi (Hungarian)
 - Nobel Prize winner for discovering Ascorbic Acid in 1937
 - Loss of wife (breast cancer)
 - Wanted to find a cure for cancer
 - Wheat germ-quinones-and ascorbic acid
- Otto Warburg
 - Cancer specific metabolism of sugars
- Avemar Research-Mate Hidvegi PhD

Otto Heinrich Warburg



Nobel Prize in Physiology or Medicine 1931 "for his discovery of the nature and mode of action of the respiratory enzyme."



Cancer cells exhibit increased glycolysis a phenomenon known as the "Warburg effect" and is considered as one of the most fundamental metabolic alterations during malignant transformation.







Fall of Communism Leads to a Blossoming of Ideas & Initiative



The fall of communism in Hungary liberated scientists from central control, and allowed independent research.

Biochemist Dr. Mate Hidvegi resumed Dr. Szent-Gyorgyi's work, patenting a technique of fermenting wheat germ with baker's yeast to produce a laboratory standard compound for research and later commercialization.



8

Mechanisms of Action of Avemar

- Inhibits glycolysis and enhances aerobic metabolism
- Immune modulation
- Induces apoptosis-programmed cell death
- Anti-angiogenesis
- Anti-metastatic
- Inhibits cancerous DNA synthesis



Inducing cancer cell suicide (Apoptosis)

Enhances the mechanisms of programmed cell death in cancer cells (referred to as "apoptosis" or cell suicide) in two complementary ways.

✓ By inhibiting the production of PARP [poly (ADP-ribose) polymerase], a DNA repair enzyme cancer cells need to reproduce.

✓ By enhancing the production of Caspase-3, an enzyme that in the absence of PARP initiates programmed cell death.

The mechanism of many anti-cancer therapies (chemotherapy, radiation, and herbal) is to induce programmed cell death, Avemar enhances their effectiveness by lowering the "threshold" of apoptosis.

RWGE inhibits głycołysis/pentose cycle enzymes and induces apoptosis through poly (ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells. J Biol Chem 277: 46408-46414, 2002. FWGE induces apoptosis and downegulation of major histocompatibility complex class I proteins in tumor T and B cell lines. Int J Oncol 20: 563-570, 2002.



Avemar helps the immune system identify cancer cells for attack.

Cancer cells try to hide from the immune system's Natural Killer (NK) cells by displaying a surface molecule called MHC-1.

MHC-1 tells NK cells, "don't attack me, I'm one of the good guys,"...

...but, research shows Avemar suppresses cancer's mask (MHC-1) resulting increased NK cell targeting and cancer cell death. ermented wheit germ extract induces apoptosis and dowrregulation of major histocompatibility complex class I roterism in tumor T and S cell lines. Int J oncol 25: 555-70, 2002.

proteins in rumor 1 and a ceil imés. In 1 Juncia Juz 565-370, 2002. Avenar triggera poptosis and downeegulation of ceil surface MHC 1 proteins in lymphoid tumor cells. Scientific meeting of the Albert Szent-Györgyi Medical and Pharmaceutical Center of the Szeged University. Szeged, Hungary, 2000.

*Proven to support overall immune strength, coordination and function (Adaptogenic)



 Finance Macrophage functioning, stimulating appropriate Tumor Necrosis Factor production and ICAM, a cytokine that enables white blood cells to pass through blood vessel walls and infiltrate tumors.

✓ Improve the ability of T-cells to respond to antigen presentation, and Bcells to respond to activation and produce appropriate antibodies.

 $\checkmark~$ Normalize balance of cellular and humoral (Th1/Th2) immune function in the immune system that results from age and stress

*Studies of the effect of Avemar on tumor necrosis factor induced cytotoxicity and on TNF production of immune cells. Institute of Biochemistry, Biological Research Center of the Hungarian Academy of Science. Szeged, 1999 *Effects of Avemar on the early events of the immune response. Institute of Genetics, Biological Research Center of the Hungarian Academy of Science. Szeged, 1999.

*Effect of Avemar on macrophages and microvascular endothelial cells. Scientific meeting of the Albert Szent-Gyorgyi Medical and Pharmaceutical Center of the Szeged University. Szeged, Hungary, 2000. Avemar's safety and toxicological profile is as well researched as its other attributes. Extensive cell line and animal testing showed no ill effects or toxicity at any level



Results of extensive human testing and follow up with thousands of subjects confirmed Avemar's safety profile.





In the opinion of the independent panel of medical, food safety and toxicology experts that confirmed Avemar's GRAS status with in accordance with FDA regulations,

"Avemar has the toxicological profile of bread."

Clinical Studies

- Anticancer Effect
 - Colorectal
 - Malignant melanoma
 - Oral cavity cancers with metastases to neck
 - Breast cancer
 - Lung cancer
 - Pediatric cancers
- Autoimmune Disorders
 - Rheumatoid arthritis and SLE

Methodical progression from *in vitro* and *in vivo* research to clinical trials

- Colorectal Cancer
- Melanoma
- Oral Cancer



*Controlled study of 170 sequential subjects with primary colorectal cancer



Control Group: Surgery and standard of care (chemotherapy, radiation and other appropriate treatment)

Treatment Group: Surgery and standard of care with Avemar, taken once per day (dose 9 grams daily) for 1 year

Evaluation at 80 months

82% reduction in new recurrences (p <.01)
67% reduction in metastasis (p <.01)
62% reduction in deaths (p <.01)

*A medical nutriment has supportive value in the treatment of colorectal cancer, *Br J Cancer* 2003 Aug 4;89(3):465-9. (Patients not randomized, but given choice of treatment)





Avemar in Metastatic Colorectal Cancer (Israeli Study)

- Double-Blind, Multicenter Clinical Study (Only Double-Blind Randomized Placebo Study)
- Dept of Medical Oncology; Chaim Sheba Medical Center; University of Tel-Aviv
- Gastrointestinal Cancers Unit; Department of Medical Oncology; Ichilov Medical Center; University of Tel-Aviv

All the patients had UICC Stage IV colorectal cancer with inoperable distant metastases

- AVEMAR group: 21 patients (16 males and 5 females) Mean age: 66.3 years (47-84 years)
- Placebo group: 15 patients (6 M and 9 F) Mean age: 62.9 years (52-76 years)

AVEMAR group: irinotecan (Campto) plus AVEMAR Placebo group: irinotecan (Campto) plus placebo









Melanoma metastases in Mice

Treatment	Number of lung metastases
	average±SD
Control group	20,0±6,0
MSC 3g/kg/day p.o.	4,0±2,1*
DTIC 60 mg/kg/day i.p.	7,0±4,3*
MSC+DTIC	0,1±0,1**

*<0,01 **p<0,001

Figure 5. Effect of the therapeutic composition (MSC+DTIC) on the number of lung metastases of B16 melanoma inoculated into the muscle of the hind leg.

±SD (SEM) ±SD (SEM) ±SD (SEM) Control group 0,84± 0,32 (0,11) 0,61± 0,35 (0,12) 185± 104 (35) MSC 3g/kg/day p.o. 0,86± 0,25 (0,08) 1,14±0,19 (0,06) 41± 34 (11)* SFU 1 0,26±0,13 (0,04) 1,09± 0,36 (0,12) 16±17 (6)** mg/kg/2 days i.p. - - -	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Treatment	Spleen mass (g)	Liver mass (g)	Number of metastases
Control group 0,84± 0,32 (0,11) 0,61± 0,35 (0,12) 185± 104 (35) MSC 3g/kg/day p.o. 0,86± 0,25 (0,08) 1,14±0,19 (0,06) 41± 34 (11)* SFU 1 0,26±0,13 (0,04) 1,09± 0,36 (0,12) 16±17 (6)** mg/kg/2 days i.p. . . . SFU+MSC 0,12±1,02 (0,008) 1,04± 0,21 (0,07) 2± 4 (1)**	$eq:spectral_$		±SD (SEM)	±SD (SEM)	±SD (SEM)
MSC 3g/kg/day p.o. 0,86± 0,25 (0,08) 1,14 ±0,19 (0,06) 41± 34 (11)* 5FU 1 0,26 ±0,13 (0,04) 1,09± 0,36 (0,12) 16±17 (6)** mg/kg/2 days i.p. - - - 5FU+MSC 0,12 ±1,02 (0,008) 1,04± 0,21 (0,07) 2± 4 (1)**	MSC 3g/kg/day p.o. 0,86± 0,25 (0,08) 1,14±0,19 (0,06) 41± 34 (11)* 5FU 1 0,26±0,13 (0,04) 1,09±0,36 (0,12) 16±17 (6)** mg/kg/2 days i.p. - - - 5FU+MSC 0,12±1,02 (0,008) 1,04± 0,21 (0,07) 2± 4 (1)** *p<0,003	Control group	0,84± 0,32 (0,11)	0,61±0,35 (0,12)	185±104 (35)
5FU 1 mg/kg/2 days i.p. 0,26 ±0,13 (0,04) 1,09±0,36 (0,12) 16±17 (6)** 5FU±MSC 0,12 ±1,02 (0,008) 1,04±0,21 (0,07) 2±4 (1)** *p<0,003	SFU 1 0,26 ±0,13 (0,04) 1,09±0,36 (0,12) 16±17 (6)** mg/kg/2 days i.p.	MSC 3g/kg/day p.o.	0,86± 0,25 (0,08)	1,14 ±0,19 (0,06)	41± 34 (11)*
SFU+MSC 0,12 ±1,02 (0,008) 1,04± 0,21 (0,07) 2± 4 (1)** *p<0,003	SFU+MSC 0,12±1,02(0,008) 1,04±0,21(0,07) 2±4(1)** *p<0,003	5FU 1 mg/kg/2 days i.p.	0,26 ±0,13 (0,04)	1,09±0,36 (0,12)	16±17 (6)**
*p<0,003	*p<0,003 **p<0,001 Figure 6. Effect of the therapeutic composition (MSC+5FU) on liver metastases of C38 colorectal carcinoma and on the mass of the parent tumor containing spleen.	5FU+MSC	0,12 ±1,02 (0,008)	1,04± 0,21 (0,07)	2±4(1)**
**p>0,001 Figure 6. Effect of the therapeutic composition (MSC+5FU) on liver metastases of C38 colorectal carcinoma and on the mass of the parent tumor containing spleen.	· · · · · · · · · · · · · · · · · · ·	*p<0,003 **p<0,001 Figure 6. Effect of the ti carcinoma and on the ma	herapeutic composition (I	MSC+5FU) on liver met	tastases of C38 colorectal

Avemar as Adjuvant in Stage III Melanoma

Cancer Biotherapy and Radiopharm, August, 2008

- Site: Blokhin Cancer Center of the Russian Medical Academy, Moscow
- Design: open, prospective, randomized Phase II
- Objective: Avemar's effects on disease outcome in high-risk melanoma patients
- Follow-up: 7 years



Enhancing quality of life in Ca patients Many natural and nutritional therapies are regarded as supportive therapies, and are not studied for their direct effect on tumors. Instead they are evaluated for benefits in terms of preventing or reversing cancer therapy related

side effects and improving quality of life. Several studies of this type have

been conducted with Avemar.



- 15 year-survival: Now 90% compared to 30%
- Avemar reduce complications so that kids could receive more chemotherapy to help cure rate

Avemar helped to prevent the chemotherapy induced suppression of immune function that lead to the life threatening opportunistic infections in children with cancer treated with chemotherapy.

Pediatric Hematology/	# of Febrile			
Oncology	Neutropenic Events (FNE)	4.2	2.7	35.71%
Edwar-Oad Anna & Koney MD, Pub	per Patient			
	Average Days Duration of FNE	8.9	6.1	31.46%
	Frequency of FNE	43.40%	24.80%	42.86%
Compare Phases (Base)		-		
and the second second second				

*Fermented Wheat Germ Extract Reduces Chemotherapy-Induced Febrile Neutropenia in Pediatric Cancer Patients, J Pediatr Hematol Oncol 26 (10), October 2004.

Avemar helped reduce side effects associated with chemotherapy and improve quality of life.





55 women with breast cancer under chemotherapy treatment studied over 3 years, showed the use of Avemar was associated with improvement in symptoms of fatigue, insomnia, nausea, vomiting and constipation, and in measures of global health, physical and emotional function. 1

39 women with breast cancer under chemotherapy treatment studied over 1.5 years, showed Avemar improved or eliminated side effect symptoms in the majority resulting in weight gain. 2

Lung Cancer

17 men and women with lung cancer under chemo and radiation treatment studied over 8 months, showed daily use of Avemar resulted in improvement in measures of fatigue, social function and global health. 3

1.Effects Of Long-Term Avemar* Treatment On Quality Of Life In Breast Cancer, Balogh A, et al, 2001 [Unpublished]. 2.Supportive Effects Of Avemar* In Breast Cancer, Balogh A, et al, 2001 (Unpublished] 3.Effects Of Avemar* Treatment On Quality Of Life In Terminal Lung Cancer, Ajkay 2, et al, 2000 (unpublished).





	Effective against all cancer cell lines teste Test tube (in vitro) studies of cell lines in culture, and animal (in vivo) studies of implanted tumors have demonstrated Avemar's anti-cancer effects against every cell line tested	d
	Lung cancer Pancreatic Lymphoma Leukemia	
U.S	Breast cancer (estrogen positive, negative and inflammatory) Prostate <i>And others</i>	76
		70



Additional Avemar Research

• ASCO 2007 Annual Meeting – Effect of Avemar on the Growth of MXT Breast Cancer Carcinoma

•Effect of Avemar on Estrogen Receptor Positive and Negative Tumor Model

•Effect of Avemar on the Growth of Pc-3 Human Prostate Tumor Xenograph in Mice





Avemar with Implanted Breast Cancers in Animals

- Avemar worked at least as well in inhibiting cancer growth as any antiestrogen
- Only one combination with Avemar was better than Avemar alone
- Avemar worked with estrogen negative cancers as well, whereas anti-estrogens did not work at all

81

Drug Interactions

- Cytostatics
 - Increases efficacy of all tested chemo agents
 - Decreases side effects and toxicity
 - Reduces neutropenic septicemia
- Increases the efficacy of anti-estrogens
- Could be administered with cytokines
- Synergistic with Imatinib mesylate (Gleevec Used in Chronic Myelogenous Leukemia or CML) and antagonizes resistance
- Ascorbic acid may attenuate the effect of Avemar and should be taken at orally at least 2 hours away from it.

Summary

- Avemar inhibits cancer specific metabolism using multiple modes of action
- Synergistic with cytostatics
- Efficacy (in clinical studies) colorectal and oral cavity cancer, melanoma
- Decrease in febrile neutropenia episodes
- Improvement of QOL
- No adverse health effects
- Available for patients in need

Avemar: Administration & Cost

- One box = 1 month supply, 30 packets per box
- Each packet contains 17g of powder, 8.5g of Avemar Pulvis, 9g of low glycemic fructose, naturally orange flavored
- Take one packet per day, preferably 2 hours away from food, medication or other supplements
- Retail Price: \$199.95 Per Month, \$6.67 Per Day
- Generally, not covered by insurance

<section-header><section-header><image><image><image>

Active Hexose Correlated Compound (AHCC)

- Naturally-derived complex compound: - Created by reacting specific enzymes with
 - Several subspecies of hybridized medicinal mushrooms
- Unique compound formed through proprietary cultivation method and a patented manufacturing process
 - Not a mushroom complex
 - Low molecular weight of 5,000 Daltons as compared to other immune ingredients
 - (rice bran, beta-glucans and standard mushroom extracts are usually ~200,000 Daltons)

Active Hexose Correlated Compound (AHCC) 2

- Biological response modifier with strong immunomodulating properties
- Shown in scientific research to increase activity of white blood cells
 - White blood cells protect against & destroy abnormal cells (viruses, bacteria, parasites)
 - Increased activity of Natural Killer (NK), B, B
 Helper, Killer T, Lymphokine Activated Killer (LAK)
 cells, Macrophage and Cytokines



The Case for AHCC

- Supported by over 100 studies
 - Over 4,000 patients have been involved in clinical trials
 - Researched by over 30 prestigious institutions
 - worldwide
 - New studies presented annually at the AHCC Research Symposium
- Used in over 700 clinics worldwide
- Over 17 years of use in Japan and 6 years in the U.S.
- #1 Selling Immune Supplement in Japan
- Subject of more than 10 books in Japan
- Won multiple recognitions including Nutracon Best Product (2002)

AHCC Research in the U.S.A.

- Univ. of Texas, Anderson Cancer Center
- University of California, Davis Cancer Center
- Brigham and Women's Hospital (Harvard)
- Faulkner Hospital (Harvard)
- Columbia Presbyterian (Holistic Urology)
- Yale School of Medicine, Rheumatology
- SUNY Binghamton, Biological Sciences
- University of Texas, Houston Medical, Surgery
- Drexel University, Bioscience and Biotechnology

Science and Research behind AHCC

The Immune System - Physiology

- Complicated series of cells that include:
 - Natural killer (NK-cells)
 Cytokines

Mast cells

- Macrophages
 Interleukins
- T and B cells
- Substances they release
 - Histamines
 - Leukotrienes
- Others

Misfiring of the Immune System

- Assault on the immune systems causes:
 - Decreased functioning of the natural killer (NK) cells
 - Decreased functioning of the T-cells and
 - macrophages – Suppression of IL-2
 - Overproduction of IL-6 and other inflammatory cytokines
- Long-term impact: chronic illness
- Immune system: key health and should be a key focus of preventive medicine

Natural Killer Cells

- Serves a dual function
 - Cytotoxic destroyer
 - Immunoregulator
- Sentinel cells
 - First line of defense against invading pathogens (viruses, bacteria, cancer cells)
- Critical Role of NK cells
 - Cancer sells are produced continuously in the body
 - NK cells must remove them before they multiply

Proper functioning of NK cells is critical to human health

AHCC and NK Cells

- Increases NK cell activity by 300-fold
 - Stimulates T-cells
 - Stimulates Macrophages
 - Stimulates Cytokines
- Appears to be able to stimulate and modulate
- Works on both the macrophages and the cytokines
 Valuable links and network messengers
- Can work in auto-immune disorders because it does not
- over-stimulate the immune system
- AHCC has a built-in dampening system
- Can be taken continuously
 - Does not need to be stopped like other immune-enhancing supplements

AHCC improves the Prognosis of Liver Cancer after Surgery

- Although AHCC has shown in In vitro experiments that it enhances natural killer cell activity, the effects of AHCC in a clinical setting have not been reported
- Aim of study was to determine if AHCC can improve the prognosis of hepatocellular carcinoma (HCC) patients following surgical treatment.
- Prospective cohort study was performed from February 1, 1992 to December 31, 2001. A total of 269 consecutive patients with histologically confirmed HCC were studied.
- All of the patients underwent resection of a liver tumor.
- Time to treatment failure (disease recurrence or death) and ten parameters related to liver function after surgery were examined.

AHCC improves the Prognosis of Liver Cancer after Surgery-2

- RESULTS: Of the 269 patients, 113 received AHCC orally after undergoing curative surgery (AHCC group). The AHCC group had a significantly longer no recurrence period and an increased overall survival rate when compared to the control group by Cox's multivariate analysis.
- CONCLUSIONS: This study suggests that AHCC intake can improve the prognosis of postoperative HCC patients.
- J Hepatol. 2002 Jul;37(1):78-86. Comment in: J Hepatol. 2002 Jul;37(1):147-50. Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, Kwon AH, Kamiyama Y. First Department of Surgery, Kansai Medical University, 10-15 Fumizono, Moriguchi, Osaka 570-8507, Japan. matsui@Hakii.kmu.ac.jp

AHCC Improves Survival in Patients with Advanced Liver Cancer

- Prospective cohort study-44 patients-confirmed liver cancer
- Survival time, quality of life, clinical and immunological parameters related to liver function, cellular immunity, and patient status were determined.
- 34 patients received AHCC and 10 received placebo
- Patients in the AHCC treated-group had a significantly prolonged survival when compared to the control group by Mann-Whitney test (95% Cl, p = 0.000).

AHCC Improves Survival in Patients with Advanced Liver Cancer-2

- Quality of life in terms of mental stability, general physical health status, and ability to have normal activities were significantly improved after 3 months of AHCC treatment when tested using the Wilcoxon signed-rank test (on one-sided test, p = 0.028, 0.037, and 0.040, respectively).
- Conclusion: AHCC could prolong the survival and improve the QOL-patients with advanced liver cancer
- Asian Pac J Allergy Immunol. 2006 Mar;24(1):33-45. Cowawintaweewat S, et al Faculty of Allied Health Sciences, Thammasat University Rangsit Campus,Patumthani, Thailand.]

.

.

Adding AHCC to Treat GI & Breast Cancers at Fujimoto Hospital

- Presented at 6th AHCC Symposium (1998) and 8th AHCC Symposium (2000)
- Yusuf Kawaguchi MD, PhD-Asst Prof-Dept of Surgery, Kansai Medical University
- 127 patients with breast or GI cancers (gastric and colon) treated for 3 years and 3 months
- Mean survival rates and mean survival times in several stages improved compared to those average rates in Japan

100

102

• Quality of life also improved

Type of Cancer	Stage	Cases No.	Dead/Total	MST (months)	MSR (%)	Average MSR in Japan
Breast	0-1	6	0/6		100	
Breast	II	8	0/8		100	
Breast	ш	2	0/2		100	70
Breast	IV	4	2/4	30	50	35
				Mean Survival Time	Mean Survival Rate	

. .

- ..

Addition of AHCC to Gastric Cancer Patients Treated at Fujimoto Hosp (6th & 8th AHCC Symp) Cases No. Dead/Total Stage ИST ЛSR (%) Type of Cancer MSR in (months) Gastric 0-I 6 0/6 100 0/1 Gastric II 100 1 Gastric III 6 2/6 27 35 66.7 2/15 Gastric IV 15 14.4 50 8 Mean Mean Survival Survival Rate

Ad Treate	dition o ed at Fu	of AHCO ujimoto	C to Colo Hosp (6	on Can 5 th & 8 ^t	cer Pati th AHCC	ients Symp)
Type of Cancer	Stage	Cases No.	Dead/Total	MST (months)	MSR (%)	Average MSR in Japan
Colon	0-I	6	0/6		100	
Gastric	II	1	0/1		100	
Gastric	ш	6	2/6	27	66.7	35
Gastric	IV	15	2/15	14.4	50	8
				Mean Survival Time	Mean Survival Rate	
						103

Addition of AHCC to Gastric Cancer Patients Treated at Fujimoto Hosp (6th & 8th AHCC Symp) Type of Cancer Cases No. Dead/Total Stage Average MSR in (months) Colon 0-1 2 0/2 100 0/8 Colon ш 8 100 2/18 Colon Ш 18 10.2 89.9 55.9 IV 10/14 Colon 14 13.1 28.6 21.0 Mear Survival Survival Rate

AHCC + Chemo UFT Reduces Metastases in Rat Breast Cancer

- Combination had some effect on primary cancer growth and some metastatic expression
- In vitro, combo increased NK Cell activity, whereas UFT alone depressed NK
- So, benefits of AHCC with chemo mediated by immune enhancement

Matsushita K et. a. Anti-Cancer Drugs 1998, 343-350.

105

AHCC Potential for Chemotherapy Drug Interactions

- AHCC: potential for drug-drug interactions involving CYP450 2D6, such as doxorubicin (Adriamycin) or ondansetron (Zofran-used to treat nausea with chemo)
- Safe to administer with most other chemotherapy agents that are not metabolized via the CYP450 2D6 pathway
- J Soc Integr Oncol. 2008 Summer;6(3):105-9. Mach CM, Fugii H, Wakame K, Smith J. Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, TX

106

AHCC Reduces Cisplatin Evoked Adverse Effects in Tumor-Bearing Mice

- Enhanced cisplatin-induced antitumor effect in both the size (p<0.05) and weight (p<0.05)
- Increased the food intake in the cisplatintreated mice.
- Reduced kidney damage
- Reduced bone marrow due to cisplatin
- Toxicol Appl Pharmacol. 2007 Jul 15;222(2):152-8. Epub 2007 Apr 20. Hirose A, et al

AHCC Enhances Tumor Surveillance to Prevent Cancer in Mice

- Potential role of AHCC in tumor immune surveillance is unknown
- C57BL/6 mice were given AHCC or water followed by tumor cell inoculation.
- AHCC treatment significantly delayed tumor development after inoculation of either melanoma cell line B16F0 or lymphoma cell line EL4.

AHCC Enhances Tumor Surveillance to Prevent Cancer in Mice-2

- Enhanced both Ag-specific activation and proliferation of CD4(+) and CD8(+) T cells, increased the number of tumor Ag-specific CD8(+) T cells, and more importantly, increased the frequency of tumor Ag-specific IFNgamma producing CD8(+) T cells.
- Increased Natural Killer cells, improving the function of these innate-like lymphocytes.
- Conclusion: AHCC can enhance tumor immune surveillance through regulating both innate and adaptive immune responses.
- 2006 Oct;55(10):1258-66. Epub 2005 Dec 16. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Gao V, Zhang D, Sun B, Fujil H, Kosuna K, Yin Z. Section of Rheumatology, Department of Medicine, Yale School of Medicine

AHCC Cancer-Related Research

• Used in Asia and the U.S. to reduce side-effects of chemotherapy

Reduce toxicity Improve quality of life

- Research supports the following modes of action:
 - Increases Tumor Necrosis Factor
 - Increases Gamma Interferon
 - Increases IL-12 (all decrease when undergoing chemotherapy)
 - Decreases circulating level of IAP (Immuno-suppressive acidic protein)
 - Decreases circulating level of IAP and TGF-B (tumor growth
- factor-Beta)
- Multiple Studies in Japan for this Indication
 - On formulary in over 700 hospitals as adjunct to Chemotherapy and Radiation Therapy
 - Increasingly used in the U.S. with very positive reported results

Other Uses of AHCC in Clinical Practice Modulation of the Raise CD-4 counts an cytokine defense important immune system mechanism cellular component Allergies Post-Chemotherapy Asthma • HIV Chronic Sinusitis Lyme Disease Eczema Chronic Fatigue Fibromvalgia Osteoarthritis Hives Cold and Flu Prevention Rashes Cold and Flu Treatment Seasonal Disorders Hepatitis C-Liver Disorders AHCC might be used as a daily supplement for the immune system,

Why AHCC is a Useful Nutritional Supplement

- Offers an effective balance between high levels of stimulation of the NK cell mediated pathways
- Documented clinical and basic science research at prestigious hospitals around the world
- Documented efficacy studies
- Significant anecdotal evidence / positive response of patients
- Documented safety studies
- No toxicity
- · Very few and rare side-effects

Usage and Dosage

- Available as 500 mg Capsules
- Therapeutic Dosage
 - Patients with highly comprised immune systems
 - Recommended therapeutic dose: 1 gram (2 capsules) 3 times daily
- Preventive Dosage
 - Health-conscious adults seeking to heighten their immune activity
 - Recommended preventive/therapeutic does 500mg
 1g daily (1 to 2 capsules daily

1

Summary for AHCC

- Biological Response Modifier with strong immunomodulating properties
- Extensive clinical research
- Strong safety data
- Significant clinical usage
- Helpful for patients with:
 - Immune disorders
 - Liver disease
 - Cancer
 Undergoing chemotherapy
 - Ondergoing chemotherapy
 Chronic illnesses
 - Illnesses directly caused by inflammation
- Important for prevention of lifestyle diseases

114

Take Home Messages

- All women should be on a cancer (and other degenerative disease preventive program
- Offered a number of tools to help develop this program
- Women with current breast cancer or a history of breast cancer particularly should be on an intensive program
- Diet is key to any preventive program

Take Home Messages-2

- Women should be careful about decisions regarding conventional cancer treatment
- Nutritional supplements can be very helpful as part of a program
- Two supplements (Avemar and AHCC) have been discussed in some depth
- Because of complementary mechanisms, they should be useful when taken together, though no clinical research on the two together is available